ANI Pharmaceuticals (ANIP) FY2015 results: revenue $76 million, up 36.4% on the year
ANI Pharmaceuticals Inc. (ANIP) reported revenue of $76 million for fiscal 2015, the year ended 31 December 2015, up 36.4% on the year before. Net income was $15 million, down 46.5%, and diluted earnings per share $1.32. The figures are the company's own, from the 10-K it filed with the SEC on 23 February 2016.
Revenue
$76 million
+36.4% on the year
FY2009FY2015
Operating margin
42.8%
35.7% a year earlier
FY2009FY2015
Net income
$15 million
-46.5% on the year
FY2009FY2015
Diluted EPS
$1.32
-49.0% on the year
FY2009FY2015
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2015
FY2014
FY2013
On the year
Last 8 years
Revenue
76.3
56.0
30.1
+36.4%
Cost of revenue
12.7
11.5
10.0
+10.6%
Gross profit
63.6
44.5
20.1
+43.0%
Gross margin
83.4%
79.5%
66.8%
Research and development
2.9
2.7
1.7
+7.3%
Selling, general and administrative
21.2
17.9
16.4
+18.0%
Operating income
32.7
20.0
0.9
+63.5%
Operating margin
42.8%
35.7%
3.0%
Interest expense
11.1
0.8
0.5
+1,274.0%
Pre-tax income
21.7
19.4
0.1
+12.1%
Income tax
6.4
-9.4
0.0
Effective tax rate
29.3%
-48.3%
15.9%
Net income
15.4
28.7
0.3
-46.5%
Net margin
20.1%
51.4%
1.0%
Diluted EPS
$1.32
$2.59
-$0.92
-49.0%
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2015
FY2014
FY2013
On the year
Last 8 years
Operating cash flow
17.3
22.0
-5.5
-21.6%
Capital expenditure
2.2
1.1
0.2
+94.9%
Free cash flow
15.1
20.9
-5.7
-27.9%
Free cash flow margin
19.8%
37.4%
-18.9%
Cash from investing
-32.7
-35.8
n/a
Cash from financing
1.1
172
-3.7
-99.4%
Depreciation and amortisation
6.9
3.9
1.1
+77.9%
Share-based compensation
3.9
3.4
0.0
+12.6%
Buybacks
0.0
0.0
0.4
Diluted shares, weighted
12m
11m
5m
+4.6%
Balance sheet
$ million
FY2015
FY2014
FY2013
On the year
Last 8 years
Shareholders' equity
160
140
41.0
+14.5%
Debt
113
107
0.0
+6.5%
Other liabilities
11.8
13.2
3.5
-11.2%
Total liabilities and equity
285
260
44.5
+9.9%
Fixed assets
7.1
5.2
4.5
+36.5%
Goodwill
1.8
1.8
1.8
0.0%
Intangible assets
66.4
42.1
10.4
+57.8%
Cash and equivalents
155
169
11.1
-8.5%
Receivables
21.9
17.3
12.5
+26.8%
Inventory
13.4
7.5
3.5
+78.1%
Other assets
19.9
16.6
0.6
+20.0%
Total assets
285
260
44.5
+9.9%
10-K for the year ended 31 December 2015, filed 23 February 2016: the filing.